Targeting PD-L1 to improve cancer therapy
Targeting dual functions of PD-L1 for cancer therapy
['FUNDING_R01'] · MAYO CLINIC ROCHESTER · NIH-10991303
This study is exploring a new way to help cancer patients by creating a treatment that targets a protein called PD-L1, which helps cancer cells hide from the immune system, with the hope of making the cancer easier to treat.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MAYO CLINIC ROCHESTER (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-10991303 on ClinicalTrials.gov |
What this research studies
This research investigates a new approach to cancer treatment by targeting the protein PD-L1, which plays a role in helping cancer cells evade the immune system. The study aims to develop an antibody that not only blocks PD-L1's interaction with immune cells but also reduces its levels within cancer cells, potentially making them more susceptible to treatment. By disrupting PD-L1's functions, the research seeks to enhance the immune response against tumors and improve the effectiveness of existing therapies. Patients may benefit from this innovative strategy that addresses the limitations of current PD-L1 targeting methods.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced cancers that express PD-L1 and have not responded well to existing treatments.
Not a fit: Patients with early-stage cancers or those whose tumors do not express PD-L1 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that enhance the immune system's ability to fight tumors.
How similar studies have performed: Other research has shown promise in targeting PD-L1, but this approach of simultaneously addressing its intracellular functions is relatively novel.
Where this research is happening
ROCHESTER, UNITED STATES
- MAYO CLINIC ROCHESTER — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DONG, HAIDONG — MAYO CLINIC ROCHESTER
- Study coordinator: DONG, HAIDONG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Advanced Cancer, anti-cancer therapy